VTE prophylaxis.
Risk-assess every admission (Padua, IMPROVE-BLEED, Caprini), pick the agent, adjust for renal function and body size, and switch to mechanical when you can't anticoagulate. Plus orthopedics, cancer, pregnancy, and HIT — and the CrCl check everyone misses.
Reviewed June 2026 · verify against current guidelines
Assess, Start, Hold
Who needs prophylaxis
| Medical high risk | Padua ≥4 or Geneva ≥3. |
|---|---|
| Surgical | Caprini score guides intensity. |
| Low risk | Early ambulation; no drug needed. |
| High bleeding risk | IMPROVE-BLEED ≥7. Use mechanical, not drug. |
Start, hold, restart
| Start | On admission if high VTE risk and acceptable bleeding risk. |
|---|---|
| Hold | Active bleed, platelets <50k, before surgery or neuraxial procedures. |
| Restart | Once hemostasis is secure after the procedure. |
Choose Your Anticoagulant
For medical inpatients ASH 2018 suggests LMWH or fondaparinux over UFH, and over DOACs. DOACs still have a role: rivaroxaban is FDA-approved for select medical patients, and DOACs are an equal first-line alternative to LMWH after joint replacement.
Standard prophylactic dosing
| Agent | Dose / role |
|---|---|
| Enoxaparin (LMWH) | 40 mg SC daily. First-line; reduce to 30 mg if CrCl <30. |
| UFH | 5000-7500 units SC q8-12h. Preferred if CrCl <30. |
| Fondaparinux | 2.5 mg SC daily. Use in HIT history. Avoid CrCl <30. |
| DOAC | Rivaroxaban 10 mg daily (select medical or ortho). Apixaban 2.5 mg BID (ortho). |
Renal and Body Size
When standard dosing is wrong
| CrCl <30 | Enoxaparin 30 mg SC daily, or use UFH 5000 q8-12h. |
|---|---|
| Obesity (BMI ≥40) | Higher dose: enoxaparin 40 mg BID or UFH 7500 units q8h. |
| Monitoring | Routine anti-Xa not needed. Consider in extremes. |
Mechanical Prophylaxis
When bleeding risk is too high
- IPC is the preferred mechanical method. Use when bleeding risk is unacceptable.
- Graduated stockings alone do not work and may harm (CLOTS-1).
- Combine IPC with drug prophylaxis for highest-risk surgery.
- Reassess daily. Add the drug once bleeding risk clears.
IPC contraindications
| Absolute | Severe PAD or limb ischemia (ABPI <0.5). Acute DVT in that leg. |
|---|---|
| Relative | Leg wounds, grafts, dermatitis, fracture, cellulitis, massive edema, neuropathy. |
Surgery, Cancer, Pregnancy
Tailor the plan
| Joint replacement | LMWH or DOAC over aspirin (CRISTAL). DOACs OK here. |
|---|---|
| Hip fracture | LMWH preferred. Avoid DOACs (insufficient evidence). |
| Cancer inpatient | Pharmacologic px if active cancer plus acute illness. |
| Cancer ambulatory | High-risk (Khorana ≥2): consider apixaban or rivaroxaban. |
| Pregnancy | LMWH. DOACs and warfarin are contraindicated. |
| HIT (history/active) | Avoid all heparin. Use fondaparinux or non-heparin agent. |
Where Interns Slip
High-risk errors
- Adding prophylaxis to a patient already on therapeutic anticoagulation. They are already covered; do not stack.
- Ordering enoxaparin without checking CrCl. If under 30, use 30 mg daily or UFH.
- Skipping mechanical prophylaxis when the drug is held.
- Leaving prophylaxis held after a procedure. Restart when safe.
- Using stockings instead of IPC. Stockings fail alone.
- Continuing heparin as platelets fall. Think HIT.
Sources
Verify against current guidelines and local protocol before acting.
- Schunemann HJ et al. ASH 2018 guidelines: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018;2(22):3198.
- Anderson DR et al. ASH 2019 guidelines: prevention of VTE in surgical hospitalized patients. Blood Adv 2019;3(23):3898.
- Nendaz M et al. Multicentre validation of the Geneva Risk Score (ESTIMATE). Thromb Haemost 2014;111:531. High risk ≥3.
- Cuker A et al. ASH 2018 guidelines: heparin-induced thrombocytopenia. Blood Adv 2018;2(22):3360.
- Sidhu VS et al. Aspirin vs enoxaparin for VTE prophylaxis after hip or knee arthroplasty (CRISTAL). JAMA 2022;328(8):719.
- Dennis M et al. Intermittent pneumatic compression after stroke (CLOTS-3). Lancet 2013;382(9891):516.
- Dennis M et al. Thigh-length graduated compression stockings after stroke (CLOTS-1). Lancet 2009;373(9679):1958.
- Key NS et al. VTE prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 2023;41(16):3063.
- UpToDate. Prevention of VTE in acutely ill hospitalized medical adults (2026); enoxaparin renal and obesity dosing per FDA prescribing information.
- UpToDate. Prevention of VTE in adults undergoing hip fracture repair or hip/knee replacement (2026). Agent choice and duration.
Downloads
Every card for this topic — carousels and tables, print-ready for the wards or for sharing.
